Close

BridgeBio (BBIO) Announces Pact with Amgen (AMGN) to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. SPOT
4. GM
5. AMZN
6. SHW
7. AAPL
8. IBM
9. NVDA
10. MTTR


Go back to BridgeBio (BBIO) Announces Pact with Amgen (AMGN) to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C M
(NASDAQ: BBIO) Delayed: 25.46 +0.39 (1.56%)
Previous Close $25.07    52 Week High $ 
Open $25.08    52 Week Low $ 
Day High $26.26    P/E N/A 
Day Low $25.08    EPS $ 
Volume 1,122,767       

(NASDAQ: LIAN) Delayed: 0.32 --0 (-0%)
Previous Close $0.32    52 Week High $ 
Open $0.32    52 Week Low $ 
Day High $0.32    P/E N/A 
Day Low $0.32    EPS $ 
Volume 43,413